ReShape Lifesciences (OTCMKTS:RSLSD) and Nexeon MedSystems (OTCMKTS:NXNN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.
Risk and Volatility
ReShape Lifesciences has a beta of 2.03, indicating that its stock price is 103% more volatile than the S&P 500. Comparatively, Nexeon MedSystems has a beta of 12.71, indicating that its stock price is 1,171% more volatile than the S&P 500.
Earnings & Valuation
This table compares ReShape Lifesciences and Nexeon MedSystems' revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
ReShape Lifesciences | $610,000.00 | 0.00 | $-81,150,000.00 | N/A | N/A |
Nexeon MedSystems | N/A | N/A | N/A | N/A | N/A |
Nexeon MedSystems has lower revenue, but higher earnings than ReShape Lifesciences.
Profitability
This table compares ReShape Lifesciences and Nexeon MedSystems' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
ReShape Lifesciences | -668.58% | -163.22% | -52.10% |
Nexeon MedSystems | N/A | N/A | N/A |
Analyst Recommendations
This is a breakdown of current ratings for ReShape Lifesciences and Nexeon MedSystems, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
ReShape Lifesciences | 0 | 0 | 0 | 0 | N/A |
Nexeon MedSystems | 0 | 0 | 0 | 0 | N/A |
Summary
Nexeon MedSystems beats ReShape Lifesciences on 4 of the 5 factors compared between the two stocks.